Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Homeostatic Imbalance01:10

Homeostatic Imbalance

31.7K
Homeostasis is the maintenance of a stable internal environment within the body, which is crucial for the proper functioning of cells, tissues, organs, and organ systems. The body has various control mechanisms that work together to regulate various physiological parameters such as temperature, blood pressure, pH balance, and fluid balance, to name a few. These control mechanisms are based on feedback loops that can be either positive or negative.
However, sometimes these feedback loops fail,...
31.7K
Hemoglobin01:24

Hemoglobin

7.1K
Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
7.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.8K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.8K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.0K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.0K
Hematopoiesis01:21

Hematopoiesis

8.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.3K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies.

British journal of haematology·2026
Same author

Structural variant discovery and diagnostic impact in rare diseases from short-read and long-read sequencing.

medRxiv : the preprint server for health sciences·2026
Same author

RAG-mediated structural variation and its impact on relapse risk in acute lymphoblastic leukemia.

medRxiv : the preprint server for health sciences·2026
Same author

Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress.

Science advances·2026
Same author

Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells.

Cell·2026
Same author

Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention.

bioRxiv : the preprint server for biology·2026

Video Experimental Relacionado

Updated: Dec 30, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K

Estabilización del HIF para mejorar la anemia

Richard A Voit1, Vijay G Sankaran1

  • 1Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Cell
|January 18, 2020
PubMed
Resumen

Roxadustat inhibe la HIF-prolyl hidroxilasa (HIF-PHD), estimulando la producción de eritropoyetina (EPO) para el tratamiento de la anemia. Esto mejora la absorción de hierro y la anemia en pacientes con enfermedad renal crónica.

Área de la Ciencia:

  • Nefrología
  • Biología molecular
  • Farmacología

Sus antecedentes:

  • La anemia por enfermedad renal está relacionada con el deterioro de la producción de eritropoyetina (EPO).
  • El factor 1-alfa inducible por hipoxia (HIF-1α) regula la EPO.
  • La HIF-prolyl hidroxilasa (HIF-PHD) degrada el HIF-1α bajo niveles normales de oxígeno.

Objetivo del estudio:

  • Para investigar el efecto de roxadustat en el HIF-PHD.
  • Evaluar el impacto de roxadustat en la producción de EPO y la absorción de hierro.
  • Evaluar la eficacia de roxadustat en el tratamiento de la anemia en la enfermedad renal crónica (ERC).

Principales métodos:

  • Inhibición de la actividad de la enzima HIF-PHD.
  • Monitoreo de los niveles de eritropoyetina (EPO).

Más Videos Relacionados

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K

Videos de Experimentos Relacionados

Last Updated: Dec 30, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
  • Evaluación de los parámetros de absorción del hierro.
  • Evaluación clínica de la anemia en pacientes con ERC.

    • Principales resultados:

    • Roxadustat inhibe eficazmente el HIF-PHD.
    • La inhibición conduce a un aumento de la producción de EPO.
    • Mejora de la absorción de hierro y mejoría de la anemia observada en pacientes con ERC.

    Conclusiones:

    • Roxadustat es un agente terapéutico prometedor para la anemia en la ERC.
    • La inhibición de la HIF-PHD es una estrategia viable para controlar la anemia por enfermedad renal.
    • Roxadustat ofrece un nuevo enfoque para mejorar la eritropoyesis y la homeostasis del hierro.